Source: HARMONY Alliance website
The HARMONY Alliance will present new results in Acute Myeloid Leukemia (AML) at the annual congress of the European Hematology Association (EHA2022). HARMONY Partner, Dr Alberto Hernández-Sánchez of Hospital Universitario de Salamanca, will give an oral presentation. The novel insights can be used to identify high-risk patients with greater reliability and might guide treatment choices in the future.
The clinical course and prognosis of AML is variable. Many genetic mutations are known to be involved in the development or course of AML, either alone or in combination. This knowledge is already used to stratify patients in clinical practice.
Patients with an expected good prognosis usually receive less intensive treatments as they generally do not undergo allogeneic stem cell transplantation in first line.
Mutations of the NPM1 gene are usually considered as a favorable prognostic marker. However, most patients carry several additional mutations that might influence the prognosis. Large numbers of patients need to be studied to unravel the combined effect of multiple co-mutations on the disease prognosis.
The HARMONY Big Data Platform provides an excellent infrastructure to address this problem because it collates clinical and genomic data from almost 7,000 AML patients from approx. 6 European countries. In total the HARMONY Alliances has identified over 115,000 data sets for various blood cancers, of which already over 62,000 data sets are collected. The HARMONY data lake is one of the largest databases of its kind.
“Analysis of large databases allows the discovery of co-mutations with prognostic value in AML. This might improve patient treatment choices in the future”.
Dr Alberto Hernández-Sánchez of Hospital Universitario de Salamanca:
Read full press release here.